Physician profile
Danny A Newman
NPI 1255361754
$1,572.97
in general payments reported to CMS, 2019-2025
27 companies · $240 in 2025
The $240 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $406 · 2020: $147 · 2021: $69.40 · 2022: $210 · 2023: $215 · 2024: $284 · 2025: $240.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $740.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $739.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $251.23 | 2019-2024 | |
| Amgen INC. | $216.05 | 2019-2024 | Repatha, Otezla |
| Novartis Pharmaceuticals Corporation | $188.90 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $101.64 | 2023-2025 | Xifaxan, Trulance |
| Glaxosmithkline, LLC. | $83.20 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.15 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $67.34 | 2019-2023 | Farxiga |
| Allergan, INC. | $59.32 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $51.69 | 2023 | Quviviq |
| Amarin Pharma, INC. | $50.51 | 2019-2020 | |
| Abbvie INC. | $44.07 | 2022-2023 | |
| E.R. Squibb & Sons, L.L.C. | $38.81 | 2019-2021 | |
| Novo Nordisk INC | $37.65 | 2019-2022 | |
| Lilly USA, LLC | $37.27 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $31.26 | 2019-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $31.08 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $30.07 | 2019-2024 | Gardasil 9, Gardasil, Capvaxive |
| Vital Connect, INC | $26.50 | 2025 | Vitalpatch Rtm |
| Bayer Healthcare Pharmaceuticals INC. | $23.22 | 2023 | |
| Janssen Pharmaceuticals, INC | $22.62 | 2019 | |
| Axonics, INC. | $18.40 | 2022 | |
| Exact Sciences Corporation | $16.98 | 2025 | Cologuard Collection Kit |
| Inspire Medical Systems, INC. | $16.01 | 2025 | Inspire |
| Takeda Pharmaceuticals U.S.A., INC. | $14.84 | 2019 | |
| Fresenius USA Marketing, INC. | $14.56 | 2024 | Velphoro |
| Esperion Therapeutics, INC. | $14.38 | 2025 | Nexletol |
| Sanofi Pasteur INC. | $12.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danny Newman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.